67496-78-0

Usage

Uses

Used in Pharmaceutical Industry:
Quinuclidin-4-yl methanamine is used as a ligand in the development of pharmaceuticals and drug compounds for its ability to bind to a central atom to form a coordination complex. This property makes it a valuable component in the creation of new medications and therapies.
Used in Medicinal Chemistry Research:
Quinuclidin-4-yl methanamine is used as a research compound in medicinal chemistry to study its interactions with various biological targets and to develop new drug candidates. Its role as a ligand allows researchers to explore its potential in modulating biological processes and treating diseases.
Used in Drug Design and Synthesis:
Quinuclidin-4-yl methanamine is used as a building block in the design and synthesis of new drug molecules. Its chemical properties and ability to form coordination complexes make it a useful component in the creation of novel therapeutic agents with potential applications in various medical fields.

InChI:InChI=1S/C8H16N2/c9-7-8-1-4-10(5-2-8)6-3-8/h1-7,9H2

Upstream product

• 26458-78-6 4-cyanoquinuclidine 

Downstream Products

• 165379-18-0 N-(1-azabicyclo[2.2.2]octan-4-ylmethyl)-2'-oxo-spiro[cyclopropane-1,3'-[3'H]indole]-1'(2'H)-carboxamide 
• 167753-24-4 3-(quinuclidin-4-yl)methyl-4-phenyl-3,4-dihydro-2(1H)-quinazolinone 
• 1135935-59-9 N-(quinuclidin-4-ylmethyl)-1H-indole-3-carboxamide 
• 1186331-94-1 3-(7-{6-[(1-azabicyclo[2.2.2]oct-4-ylmethyl)amino]pyridin-3-yl}-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)phenol 
• 1186334-45-1 N-(1-aza-bicyclo[2.2.2]oct-4-ylmethyl)-[3-(3-methoxy-phenyl)-2-pyridin-4-yl-pyrazolo[1,5,a]pyrimidin-7-yl]-amine 
• 1236120-93-6 C₁₈H₂₀ClN₃OS 
• 1236121-57-5 C₂₁H₂₃ClN₂O 
• 1262420-78-9 lithium 3-((quinuclidin-4-ylmethylamino)methyl)-1H-indazole-4-carboxylate 
• 1262419-61-3 4-(quinuclidin-4-ylmethyl)-3,4-dihydropyrazolo[3,4,5-de]isoquinolin-5(1H)-one 
• 1262420-77-8 methyl 3-((quinuclidin-4-ylmethylamino)methyl)-1H-indazole-4-carboxylate 
• 1262420-81-4 methyl 1-(2-(quinuclidin-4-ylmethylamino)ethyl)-1H-indazole-7-carboxylate 
• 1225209-21-1 2-chloro-3,4-bis((4-methoxybenzyl)oxy)-N-(quinuclidin-4-ylmethyl)benzamide 
• 1338730-21-4 C₃₅H₃₇N₃O₅ 
• 1338729-18-2 C₂₂H₂₇N₃O₄ 

Relevant academic research and scientific papers

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).

CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP

A compound of the formula: wherein X is —N═, —CH═, or the like; W is —CH2— or the like; U is —S— or the like; R1 and R2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like; Q is a single bond or the like; R3 is hydrogen or the like; Ring A is a 6-membered aromatic heterocyclic group having 1-3 nitrogen atoms; each R4 is independently hydrogen, halogen, or the like; m is an integer from 0 to 2; G is —C(═O)— or the like; D is a single bond, —NH—, or the like; and E is a cyclic quaternary ammonium group, or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.

2′ Biaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR

Biaryl amides were discovered as novel and subtype selective M1 muscarinic acetylcholine receptor agonists. The identification, synthesis, and initial structure-activity relationships that led to compounds 3j and 4c, possessing good M1 agonist potency and intrinsic activity, and subtype selectivity for M1 over M2-5, are described.

4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF

The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.

THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS

The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease

Pleuromutilin derivatives as antimicrobials

The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.

Pyrimido[5,4]-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-methyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine, and 4-[(3-Chloro-4-fluorophenyl)amino]-6-[trans-4-dimethyl-aminocycohexylamino]pyrimido[5,4-d]pyrimidine.

INDOLONES USEFUL AS SEROTONERGIC AGENTS

This invention relates to compounds of the formula: STR1 which are useful as 5-HT 4 agonists or antagonists and 5-HT 3 antagonists.